# A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia

> **NCT01355068** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Epanutin Infatabs (Phenytoin)
- **DRUG:** Dilantin Infatabs (Phenytoin)

## Key facts

- **NCT ID:** NCT01355068
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355068, "A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01355068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*